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Summary 
Objectives 
Few international population-based studies have provided information on potential determinants of 
international disparities in cancer survival. This population-based study was aimed to identify the 
principal differences in disease characteristics and management that accounted for previously observed 
poorer survival in English compared to French patients with colorectal cancer 
Methods 
The study population comprised all cases of colorectal cancer diagnosed between 1997 and 2004 in 
the areas covered by three population-based cancer registries in France and one in England (N= 40 613). 
To investigate the influence of clinical and treatment variables on survival, we applied multivariable 
excess hazard modelling based on generalised linear models with Poisson error. 
Results 
Poorer survival for English patients was primarily due to a larger proportion dying within the first 
year after diagnosis. After controlling for inter-country differences in the use of chemotherapy and 
surgical resection with curative intent, country of residence was no-longer associated with 1-year 
survival for advanced colon cancer patients  (EHR = 0.99 (0.92-1.01), p = 0.095)). Longer-term (2-5 years) 
excess hazards of death for colon and rectal cancer patients did not differ between France and England. 
Conclusion 
This study suggests that difference in management close to diagnosis ofcolon and rectum cancer is 
related to difference in survival observedbetween France and England.Every efforts (Collection and 
standardization of additional variables such as co-morbidity) to investigate the reasons for this disparities 
in management between these two countries, and more generally across Europe, should be encouraged.  
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Introduction 
 
Survival for patients with colorectal cancer varies notably between European countries. As reported 
by the CONCORD study (Coleman et al, 2008) in 2008, 5-year relative survival for colorectal cancer in 
France was 55.6% for men and 61.5% for women, which constituted the highest survival in Western 
Europe and second best in the world for women. By contrast, in England five-year relative survival was 
worse than in comparable European countries at 42.3% for men and 44.7% for women. The 
improvement in 5-year relative survival between 1988-1990 and 2000-2002 was comparable in both 
countries (+10.2% in France Vs. +10.4% in England)(Brenner et al, 2011). Under the scenario of equal 
survival in England compared to the mean European 5-year survival, between 6600 and 7500 deaths 
would have been avoided each year for patients diagnosed between 1985-1999 (Abdel-Rahman et al, 
2009). 
Some authors have suggested that these international disparities in cancer survival, in particular the 
poorer survival in England, may not be due to actual differences in survival, but rather due to differences 
in cancer registration modalities and quality (Beral & Peto, 2010). However, a recent study highlighted 
that, even under the hypothesis of extreme incorrect registration (either date of recurrence instead of 
date of diagnosis or under-registration of long survivors), differences in cancer registration would explain 
very little of the observed disparities in survival (Woods et al, 2011). Another study suggested that the 
magnitude of error in survival time due to incorrect case completeness was less than 1% for patients 
diagnosed with colorectal cancer in England (Møller et al, 2011). Moreover, registries included in the 
EUROCARE studies are broadly comparable in terms of registration methods, especially in terms of 
microscopic verification and the prevalence of death certificate only records (Berrino et al, 2007). 
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The reasons behind the international differences in survival are not well understood and many 
factors have been argued as potentially influential. For example, there is some evidence to show that the 
lower survival in England compared to Scandinavian countries is due to a high number of deaths, 
particularly amongst elderly patients, in the first three months following diagnosis (Engholm et al, 2007; 
Folkesson et al, 2009; Morris et al, 2011). This would suggest that a greater proportion of the population 
in England present with rapidly fatal disease than elsewhere in Europe.  This may be due to more English 
cases presenting with advanced disease at diagnosis, concomitant morbidity or, perhaps, experiencing a 
different quality of care to those in other European countries(Gatta et al, 2010).  
International comparisons of survival for patients with cancer are important for the planning and 
provision of national health services. However, with the notable exception of “EUROCARE high-
resolution” studies (Ciccolallo et al, 2005; Gatta et al, 2000), very few international population-based 
studies have provided information on potential determinants of international disparities in cancer 
survival. The aim of this population-based study was to identify the principal differences in disease 
characteristics and cancer management that accounted for the difference in survival observed between 
France and England for patients with colorectal cancer. 
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Materials & Methods 
Population 
The study population comprised all cases of colorectal cancer (ICD10: C18.0 to C20.9) diagnosed 
between 1997 and 2004 in the areas covered by three population-based cancer registries in France 
(Calvados, Côte d’Or and Saône et Loire: 3% of the whole national population of France) and one in 
England (the Northern and Yorkshire Cancer Information Service (NYCRIS), which covers 13.3% of the 
national population)(Table 1). The completeness and data quality of the included registries are regularly 
assessed by the International Agency for Research on Cancer (IARC) or by European Network of Cancer 
Registries (ENCR). The final population study included 40 613 patients (7891 from France and 32722 from 
England). Over the period study, 919 patients in England had a 0 days survival (2.8%) versus 18/7891 
(0.22%) in France. 
Data 
Date of birth, sex and year of diagnosis were known for all patients. Topography was classified as 
right colon (C18.0, C18.1, C18.2, C18.3 and C18.4); left colon (C18.5, C18.6 and C18.7); unknown location   
of colon cancer (C18.8 and C18.9); rectosigmoid junction (C19.9) and rectum (C20.9) (Fritz et al, 2000). 
Stage was coded using Duke’s classification: Duke’s A: Limited to mucosa; Duke’s B: Penetrating through 
muscularispropria; Duke’s C: lymph nodes involved; “Duke’s D”: a least one metastasis (Dukes, 1932). 
The unstaged category included: non-resected patients with no clinical evidence of metastases at 
diagnosis, resected patients but for whom the registry did not capture the stage, and patients who 
received potentially downstaging radiotherapy or chemoradiotherapy prior to surgery. Localized cancers 
were defined by Duke’s A & B and advanced cancers were defined by Duke’s C &D.stage at diagnosis was 
unknown for almost 18% and 7% of English and French patients respectively (proportions are 
comparable to previous studies)(Jones et al, 2009). 
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Information was collected on the type of treatment: surgical resection with curative intent within 6 
months since diagnosis (Coded as: yes or no), chemotherapy (yes or no) and radiotherapy (yes or no). 
Palliative chemotherapy and palliative radiotherapy were not recorded in NYCRIS. French registries 
captured information on all chemotherapy and radiotherapy administered irrespective of intent. 
Survival time was defined as the time duration between the date of diagnosis and the earlier of date 
of death or date of last information about vital status or the end of the study period on 31/12/2008.  
Statistical analysis 
Estimation of up-to-5-year relative survival was based on the Ederer-II approach using the user-
written Stata command strs(Estimating and modelling relative survival, available at 
http://www.pauldickman.com/). To investigate the influence of clinical and treatment variables on 
survival, we applied multivariable excess hazard modelling based on generalised linear model with 
Poisson error (Dickman et al, 2004). Excess hazard ratio (HER) were calculated with 95% confident 
intervals(Dickman et al, 2004). Time since diagnosis was split in intervals as following: 0-3 months, 3-6 
months, 6 months-1 year, 1-2 years, 2-3 years and 4-5 years. To take into account the influence of 
treatment, survival analyses were then stratified according to cancer tumour site and stage. All analyses 
were computed using STATA 12.1 software using a publicly available procedure (Estimating and 
modelling relative survival, available at http://www.pauldickman.com/). In the absence of reliable 
information on the cause of death among the cancer patients, cancer-related survival is commonly 
estimated by relative survival approach which removes from the observed, all-cause mortality the 
expected (“background”) mortality. Background mortality was provided by life tables stratified according 
to age, sex, year of diagnosis, and administrative area (Government Office Region for England and 
“Department” for France).  
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Multiple imputations by chained equations were performed to take into account missing values 
(Little & Rubin, 2002) (missing values are presented in Table 2). The imputation model incorporated the 
variables used in the analytical models (survival time, vital status, age, sex, topography, stage, year of 
diagnosis and treatments) as recently recommended (Nur et al, 2010). The imputation model was 
stratified according to country. Iterations were conducted to create 20 completed datasets, and the 
estimates were combined according to the Rubin rules (Rubin, 1987). Multiple imputation models were 
conducted using conjointly STATA 12.1 module for imputation (StataCorp. 2011. Stata: Release 12. 
Statistical Software. College Station, TX: StataCorp LP) and the user-written Stata command ice (Royston, 
2009). All results presented in the next section are based on multiple imputations. In order to test the 
robustness of our results, all analyses were repeated on complete case analysis since the relevance of 
this method depends on the missingness mechanism. 
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Results 
Management 
The distribution of year of diagnosis and sex did not differ between the cancer registries (Table 1), 
although the proportion of right colon cancers was higher in England than in France. Distribution of stage 
before and after multiple imputations is presented in Table 2. For all cancer localizations, the proportion 
of patients diagnosed at “Duke’s D” increased in both countries after multiple imputations from 27.3% to 
30.0% in France and from 27.9% to 32.7% in England for patients diagnosed with colon cancer, and from 
24.0% to 31.6% in France and from 23.2% to 28.4% in England for patients diagnosed with rectal cancer. 
Treatment modalities (chemotherapy, radiotherapy and surgical resection with curative intent within 6 
months since diagnosis) differed between the countries. Such surgical resections were performed more 
frequently in France, being used in 83.6% of patients in France vs. 73.1% in England. Whatever stage at 
diagnosis or tumour localization, the rate of patients receiving a surgical resection with curative intent 
within 6 months was higher in France than in England. This difference was limited for localized colon 
cancer (98.9% in France Vs. 96.1% in England for stage A; 99.0% in France vs. 96.3% in England for stage 
B) and more pronounced for advanced colon cancer (97.6% in France vs. 87.8 in England for stage C; 
52.4% in France vs. 32.3% in England for stage ‘D’). Concerning rectum cancer, the different in the rate of 
patients with surgical resection within 6 months increased with stage (97.6% in France vs. 93.2% in 
England for stage A; 94.6% in France vs. 87.6% in England for stage B; 86.7% in France vs. 80.8 in England 
for stage C; 32.6% in France vs. 22.8% in England for stage ‘D’). 
Survival 
The association between country of residence and relative survival was not constant over time since 
diagnosis. In survival analysis, the interaction between time since diagnosis and country of residence was 
statistically significant (p<0.001), with the gain in survival for French patients decreasing with time since 
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diagnosis. Therefore, multivariable models were stratified according to time since diagnosis (first year 
since diagnosis vs. first to 5th years since diagnosis). 
One-Year survival analyses for patients diagnosed with colon cancer 
Patients diagnosed with colon cancer living in France had a better prognosis than those living in 
England for the first year after diagnosis (EHR = 0.70 (0.66-0.75)) (Table 3, model 1). After adjustment for 
sex, age and period of diagnosis, the higher survival for French patients remained unchanged (EHR = 0.70 
(0.65-0.74)) (Table 3, model 2). After successive adjustment for tumour site (Table 3, model 3) and stage 
at diagnosis (Table 3, model 4), patients living in France still had a higher 1-year survival than those living 
in England (EHR = 0.68 (0.64-0.74)).  
To investigate the influence of treatment, survival analyses were conducted separately on localized 
cancer (Duke’s A and Duke’s B) and advanced cancer (Duke’s C and “Duke’s D”). In unadjusted analyses, 
French patients diagnosed with a localized colon cancer had a better survival than those diagnosed in 
England (EHR= 0.77 (0.65-0.93)) (Table 3, model 5a). Differences in survival decreased after adjusting for 
surgical resection with curative intent within 6 months, but country of residence was still associated with 
1-year survival (EHR = 0.82 (0.68-0.99), p = 0.038) (Table 3, model 6a). French patients diagnosed with an 
advanced colon cancer also had better survival than those diagnosed in England (EHR= 0.67 (0.63-0.72)) 
(Table 3, model 5b) in unadjusted analyses. After adjustment for surgery with curative intent, country of 
residence remained associated with 1-year survival for patients diagnosed with an advanced colon 
cancer (EHR = 0.79 (0.74-0.85)) (Table 3, model 6b). After taking into account the use of chemotherapy, 
country of residence was no more associated with 1-year survival (EHR = 0.99 (0.92-1.01), p = 0.095)) 
(Table 3, model 7b). After considering the interaction, country of residence was associated with survival 
only in the presence of chemotherapy (EHR= 0.99 (0.92- 1.07), p=0.918 in absence of chemotherapy and 
EHR=0.81 (0.69-0.94), p=0.008 in presence of chemotherapy) (Table 3, model 8b).  
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One-Year survival analyses for patients diagnosed with rectum cancer 
Similarly, after adjustment for age, sex, period of diagnosis and stage, French rectal cancer patients 
had a better 1-year-survival than English patients (EHR = 0.76 (0.68-0.86)) (Table 3, model 11). Country of 
residence was significantly associated with 1-year survival for patients diagnosed with a localized cancer 
(EHR = 0.70 (0.49-0.99), p = 0.048) (Table 3, model 11a). But, again, after further adjustment for surgical 
resection with curative intent, country of residence was no longer statistically significant (EHR = 0.74 
(0.51- 1.08)) (Table 3 model 12a). 
When the analysis was restricted to include patients with advanced rectal cancer only, 1-year 
survival remained higher in France (EHR = 0.69 (0.61-0.77)) (Table 3, model 11b). After taking into 
account surgical resection with curative intent and radiochemotherapy, country of residence was no-
longer associated with 1-year survival (EHR = 0.96 (0.85-1.09), p = 0.2372) (Table 3, model 13b). 
Patients diagnosed with colon cancer who had survived at least one year  
Amongst colon cancer patients longer-term (2-5 years) excess hazards of death were comparable in 
both countries even after adjusting for age, sex, tumor localization and year of diagnosis (EHR = 1.02 
(0.95 – 1.11)) (Table 4, model 3). However, adjustment for stage at diagnosis shows that these patients 
had a better survival in France than in England (EHR = 0.92 (0.85-0.99), p=0.016) (Table 4, model 4). 
Longer-term (2-5 years) excess hazards of death were comparable in both countries either for localized 
colon cancer (EHR =1.05 (0.85-1.31)) (Table 4, model 5a) or for advanced colon cancer (EHR =1.03 (0.95 – 
1.12)) (Table 4, model 5 b).  
Patients diagnosed with rectum cancer who had survived at least one year  
Similarly, longer-term (2-5 years) excess hazards of death for rectal cancer patients were comparable 
in both countries after adjusting for age, sex and stage at diagnosis (EHR =0.91 (0.81 – 1.03)) (Table 4, 
Model 11). However, English patients diagnosed with an advanced rectum cancer had a better long-term 
survival than those living in France (EHR= 1.17 (1.03 – 1.31)) (Table 4, model 11b). After adjustment for 
11 
 
surgical resection with curative intent, longer-term (2-5 years) excess hazards of death were comparable 
in both countries (EHR= 1.06 (0.93- 1.21)) (Table 4, model 12b). 
Complete case analysis results 
As explained in methods section, all survival analyses were repeated in the framework of complete 
case analysis (Table 3, 4). The results of these analyses were comparable to those performed using 
multiple imputation and are therefore not repeated here. The only exception concerned the influenced 
of treatment variables (surgical resection with curative intent, chemotherapy and radiotherapy) on the 
longer-term (2-5 years) excess hazards of death for patients diagnosed with an advanced rectum cancer. 
In the Framework of complete case analyses, patients living in England still had a better survival than 
French patients (Table 4, model 5b, 6b and 7b).  
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Discussion  
This study confirms that over the study period five-year colon and rectal cancer survival was higherin 
France than in England. This difference was primarily due to a larger proportion of English patients dying 
within the first year after their diagnosis and if an individual survived a year after their diagnosis then the 
difference in survival between the countries was no longer statistically significant. This study also 
demonstrates differences in the management of patients between the countries with surgery being used 
significantly less frequently in England compared to France, these different surgery proportions being 
related to the survival difference observed.  
Potential differences between the datasets collected in each country need to be considered. Indeed, 
the lack of detail on types of surgery undertaken in the English registry data forced us to limit it to 
surgical resection with curative intent undertaken within the first six months after the diagnosis. 
Similarly, the French registries captured information on all chemotherapy and radiotherapy administered 
irrespective of intent whereas NYCRIS did not. Efforts have been made to address these differences in 
these analyses by attempting to limit the French treatment information included to that comparable to 
the English data. But, for future analyses, it would be highly desirable to have more detailed treatment 
datasets that included information on these factors to enable more robust comparisons. 
Likewise, differences may exist in the English and French datasets in relation to other important 
variables such as stage. NYCRIS aims to collect stage at diagnosis and as neo-adjuvant treatments can 
downstage rectal tumours those receiving them were classified as “not staged”. In addition, accurate 
staging requires accurate pathological assessment of a resected tumour specimen.  NYCRIS had a lower 
proportion of major resection, so a lower proportion of resected specimens and, therefore, a lower 
proportion of patients in which a robust stage could be captured.The recording of stage improved 
considerably in the NYCRIS data from 1998 onwards (registry merger in 1997) . To test if our findings 
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were influenced by this change, an analysis restricted to 1998-2004 data was conducted which provided 
similar findings (results not presented). 
Missing data multiple imputation was undertaken in our study  for dealing with missing values (Nur 
et al, 2010). Unfortunately, given the reasons for the lower staging proportion in England compared to 
France, the missing values for stage at diagnosis were probably not missing at random (i.e. patients with 
missing stage tend to have a more advanced disease than others), which could reduce the robustness of 
our results, since the effect of the absence of treatment in survival could be under-estimated. But, to our 
knowledge, no unbiased method exists for taking into account missing values not at random. 
Another limitation of this study is the small proportion of the French population covered by the 
French digestive cancer registries (3% of the whole national population), whilst NYCRIS data represents 
13.3% of the national population of England. Such a limitation is usual for population–based studies in 
France since information on stage at diagnosis and treatment are not routinely available in all French 
cancer registries but only in specialised cancer registries. The 3 specialised digestive cancer registries in 
France are located in Calvados, Côte d’Or and Saone et Loire, these areas being mainly rural,two of them 
having a reference cancer centre (University hospital and cancer care centre) in their regional capital. It is 
noteworthy  that French colorectal cancer one- and five year-relative survival calculated in this study 
were very closed to thoseestimated on all French cancer registries, which cover about 17% of the French 
population (Bossard et al, 2007). . 
In a previous study, the difference in observed survival between Europe and America was mainly 
explained by the stage at diagnosis (Gatta et al, 2000). Our study does not give such importance to stage 
at diagnosis in explaining the difference in relative survival between England and France. In a more 
recent study of relative survival which included 10 European cancer registries (from Italy, France, 
Netherlands, Spain and UK) and 9 US cancer registries, the role of surgical practices (curative resection) 
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appeared to be as important as stage at diagnosis (Ciccolallo et al, 2005). In 1990, a randomised trial 
reported that chemotherapy improved survival for stage III colon cancer (Moertel et al, 1990). European 
guidelines for the management of colon cancer also recommended the prescription of adjuvant 
chemotherapy for stage II colon cancer for which the number of lymph sampling is <12, the tumours are 
poorly differentiated, vascular or lymphatic or perineural invasion has occurred, or presentation is 
emergency and at pT4 stage (Labianca et al, 2010). Chemotherapy is also recommended for metastatic 
colon and rectum tumours. Studies comparing adjuvant therapy uptake between countries are rare 
because such detailed data are not usually available at a population level. Nevertheless, a recent study 
highlights that proportions of adjuvant therapies differed notably between European areas either for 
stage II or stage III tumours (Gatta et al, 2010). For example, 60.6 % of patients diagnosed with stage II 
colon cancer received adjuvant chemotherapy in Slovakia and only 5.3% of such patients received 
adjuvant therapy in Estonia. Our study confirmsthat this variation chemotherapy uptake across countries 
could be a potential explanation of difference in 1-year survival of advanced colon cancer. 
If differences in data quality can be dismissed then the lower treatment proportions and their 
relationship to survival must be real. What is not apparent from the results is, however, why the 
treatment proportions in England are lower. There are two potential explanations that could account for 
this. Firstly, it may be that there are fundamental differences in the characteristics of the two general 
populations that make fewer English patients eligible for active treatments. For example, English people, 
including cancer patients, may have a higher prevalence and/or severity of co-morbid disease that limits 
how these treatments could be employed.  
A second alternative explanation maybe, however, that there were real differences in the overall 
management of the cancer patients between the countries during this time period. Such a difference in 
treatment could partly be explained by differences in medical practices and/or in patient behaviour. 
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Since indication for surgery was clearly defined by international guidelines, there is no reason to suppose 
that the practice of an English surgeon would differ to a French one for a given patient. Instead, health 
care system organization offers a likely explanation for this difference in surgery indication. Indeed, 
therapeutic delay (time since diagnosis to first treatment) is notably longer in England (Robertson et al, 
2004) compared to France(Dejardin et al, 2004) even if this topic remains poorly investigated in France. 
Nevertheless, the influence of therapeutic delay on survival is highly controversial (Ramos et al, 2007) 
and, thus, is likely to explain only a part of this difference. Beside medical practices, patient behaviour 
towards diseases could differ between France and England. Indeed, time from first symptom to 
diagnosis, as well as timefrom diagnosis to staging is influenced by behaviour towards 
symptoms(Mitchell et al, 2008), and therefore could influence the distribution of stage between the 
countries. Whilst this study suggests that stage at diagnosis has no impact on the inter-country gap in 
survival, we cannot exclude the possibility that English patients had more co-morbidities than French 
ones for a given stage at diagnosis. Further studies are needed to investigate this additional potential 
explanation for the gap in survival. 
During the period study, major reforms were initiated with the publication of national cancer plans 
in England in 2000(Health, 2000)and in France in 2003 (available online at http://www.plan-
cancer.gouv.fr/). A recent study highlights some beneficial impact of NHS cancer plan in England. For 
example, the 3-year relative survival for colon cancer increased from 53.5% during the period 1996-2000 
to 57.6% for the period 2004-2006 (Rachet et al, 2009). Since survival data are not yet published for 
France, we cannot compare the effectiveness of the French and English cancer plan.  
Every effort to investigate the reasons for such disparities between these two countries, and more 
generally across Europe, should be encouraged. Collection and standardization of additional variables 
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such as co-morbidity, anaesthetic risk and treatment pathways may be crucial for a better understanding 
of underlying mechanisms of inter-country differences in survival of patients with cancer. 
Acknowledgments 
The authors thank the French National cancer institute and the “Fondation de France”, which 
provided financial support for this study. BR and EM are supported by Cancer Research UK 
(C1336/A5735 andC23434/A9805 respectively) 
17 
 
References 
 
Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman MP (2009) What if cancer survival in 
Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer101 Suppl 2: S115-24 
 
Beral V, Peto R (2010) UK cancer survival statistics. BMJ341: c4112 
 
Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Lasota MB, Coebergh JW, Santaquilani M 
(2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-
99: results of the EUROCARE-4 study. Lancet Oncol8(9): 773-83 
 
Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, Guizard AV, Tretarre B, Launoy G, 
Colonna M, Danzon A, Molinie F, Troussard X, Bourdon-Raverdy N, Carli PM, Jaffre A, Bessaguet C, 
Sauleau E, Schvartz C, Arveux P, Maynadie M, Grosclaude P, Esteve J, Faivre J (2007) Survival of cancer 
patients in France: A population-based study from the Association of the French Cancer Registries 
(FRANCIM). European Journal of Cancer43(1): 149-160 
 
Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, Mangone L, Francisci S, Group tEW 
(2011) Progress in colorectal cancer survival in Europe, from the late 1980s to the early 21st century: The 
EUROCARE study. Int J Cancer 
 
Ciccolallo L, Capocaccia R, Coleman MP, Berrino F, Coebergh JWW, Damhuis RAM, Faivre J, Martinez-
Garcia C, Moller H, de Leon MP, Launoy G, Raverdy N, Williams EMI, Gatta G (2005) Survival differences 
between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. 
Gut54(2): 268-273 
 
Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, 
Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, E Silva GA, Francisci S, 
Santaquilani M, Verdecchia A, Storm HH, Young JL (2008) Cancer survival in five continents: a worldwide 
population-based study (CONCORD). Lancet Oncol9(8): 730-56 
 
Dejardin O, Herbert C, Velten M, Buemi A, Menegoz F, Maarouf N, Launoy G (2004) Social and 
geographical factors influencing the delay in treatment for colorectal cancer. British Journal of 
Cancer91(9): 1751-1752 
 
Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat 
Med23(1): 51-64 
 
Dukes C (1932) The classification of cancer of the rectum. Journal of Pathology & Bacteriology35: 9 
18 
 
 
Engholm G, Kejs AM, Brewster DH, Gaard M, Holmberg L, Hartley R, Iddenden R, Møller H, Sankila R, 
Thomson CS, Storm HH (2007) Colorectal cancer survival in the Nordic countries and the United 
Kingdom: excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000. Int J 
Cancer121(5): 1115-22 
 
Folkesson J, Engholm G, Ehrnrooth E, Kejs AM, Påhlman L, Harling H, Wibe A, Gaard M, Thornorvaldur J, 
Tryggvadottir L, Brewster DH, Hakulinen T, Storm HH (2009) Rectal cancer survival in the Nordic 
countries and Scotland. Int J Cancer125(10): 2406-12 
 
Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin Dm, Whelan S (2000) International 
Classification of diseases for Oncology - Third Edition. Geneva: World Health Organization 
 
Gatta G, Capocaccia R, Sant M, Bell CM, Coebergh JW, Damhuis RA, Faivre J, Martinez-Garcia C, Pawlega 
J, Ponz de Leon M, Pottier D, Raverdy N, Williams EM, Berrino F (2000) Understanding variations in 
survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut47(4): 533-8 
 
Gatta G, Zigon G, Aareleid T, Ardanaz E, Bielska-Lasota M, Galceran J, Góźdź S, Hakulinen T, Martinez-
Garcia C, Plesko I, Zakelj MP, Rachtan J, Tagliabue G, Vercelli M, Faivre J (2010) Patterns of care for 
European colorectal cancer patients diagnosed 1996-1998: a EUROCARE high resolution study. Acta 
Oncol49(6): 776-83 
 
Health Do (2000) The NHS Cancer plan, Health Do (ed). London: Department of Health 
 
Jones AM, Morris E, Thomas J, Forman D, Melia J, Moss SM (2009) Evaluation of bowel cancer 
registration data in England, 1996-2004. Br J Cancer101(8): 1269-73 
 
Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, Group EGW (2010) Primary colon cancer: 
ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol21 Suppl 5: 
v70-7 
 
Little R, Rubin D (2002) Statistical analysis with missing data. Hoboken, New Jersey: John Wiley & Sons, 
Inc. 
 
Mitchell E, Macdonald S, Campbell NC, Weller D, Macleod U (2008) Influences on pre-hospital delay in 
the diagnosis of colorectal cancer: a systematic review. Br J Cancer98(1): 60-70 
 
19 
 
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, 
Tormey DC, Glick JH (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon 
carcinoma. N Engl J Med322(6): 352-8 
 
Morris EJ, Sandin F, Lambert PC, Bray F, Klint A, Linklater K, Robinson D, Påhlman L, Holmberg L, Møller H 
(2011) A population-based comparison of the survival of patients with colorectal cancer in England, 
Norway and Sweden between 1996 and 2004. Gut60(8): 1087-93 
 
Møller H, Richards S, Hanchett N, Riaz SP, Lüchtenborg M, Holmberg L, Robinson D (2011) Completeness 
of case ascertainment and survival time error in English cancer registries: impact on 1-year survival 
estimates. Br J Cancer105(1): 170-6 
 
Nur U, Shack LG, Rachet B, Carpenter JR, Coleman MP (2010) Modelling relative survival in the presence 
of incomplete data: a tutorial. Int J Epidemiol39(1): 118-28 
 
Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, Ellis L, Walters S, Forman D, Steward J, 
Coleman MP (2009) Population-based cancer survival trends in England and Wales up to 2007: an 
assessment of the NHS cancer plan for England. Lancet Oncol10(4): 351-69 
 
Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguiló A (2007) Relationship of diagnostic and 
therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer43(17): 2467-78 
 
Robertson R, Campbell NC, Smith S, Donnan PT, Sullivan F, Duffy R, Ritchie LD, Millar D, Cassidy J, Munro 
A (2004) Factors influencing time from presentation to treatment of colorectal and breast cancer in 
urban and rural areas. British Journal of Cancer90(8): 1479-1485 
 
Royston P (2009) Multiple imputation of missing values: Further update of  ice, with an emphasis on 
categorical variables. STATA Journal9(2): 11 
 
Rubin D (1987) Multiple Imputation for Nonresponse in Surveys. New-York: John Wiley & Sons 
 
Woods LM, Coleman MP, Lawrence G, Rashbass J, Berrino F, Rachet B (2011) Evidence against the 
proposition that "UK cancer survival statistics are misleading": simulation study with National Cancer 
Registry data. BMJ342: d3399 
 
 
 
20 
 
Table 1 : Patients diagnosed with colorectal cancer in two European countries between 1997-2004 (N=40 613) 
 
Calvados Côte d'Or Saone et Loire England (Nycris) P-values 
  N= 2481 N= 2329 N= 3081 N= 32722   
Variables N % N % N % N % 
 Sex 
        
0.402
Men 1359 54.8% 1300 55.8% 1683 54.6% 18176 55.5% 
 Women 1122 45.2% 1029 44.2% 1398 45.4% 14546 44.5% 
 Age 
        
0.001 
<61 523 21.1% 482 20.7% 508 16.5% 5865 17.9% 
 61-69 475 19.1% 452 19.4% 672 21.8% 7200 22.0% 
 70-79 712 28.7% 641 27.5% 893 29.0% 9418 28.8% 
 >=79 771 31.1% 754 32.4% 1008 32.7% 10239 31.3% 
 Topography 
        
<0.001 
Right colon 765 30.8% 740 31.8% 1024 33.2% 8881 27.1% 
 Left Colon 715 28.8% 717 30.8% 923 30.0% 7917 24.2% 
 Unknown Colon * 65 2.6% 18 0.8% 7 0.2% 2879 8.8% 
 Recto-sigmoidejunction 235 9.5% 355 15.2% 326 10.6% 3269 10.0% 
 Rectum 701 28.3% 499 21.4% 801 26.0% 9776 29.9% 
 Duke's stage 
        
<0.001 
A 390 15.7% 409 17.6% 567 18.4% 3724 11.4% 
 B 676 27.2% 713 30.6% 872 28.3% 8567 26.2% 
 C 592 23.9% 477 20.5% 657 21.3% 7686 23.5% 
 "D" 644 26.0% 543 23.3% 743 24.1% 7234 22.1% 
 Unstaged 179 7.2% 187 8.0% 242 7.9% 5511 16.8% 
 Year of diagnosis 
       
0.007 
1997 287 11.6% 267 11.5% 393 12.8% 3782 11.6% 
 1998 305 12.3% 258 11.1% 389 12.6% 4079 12.5% 
 1999 300 12.1% 287 12.3% 351 11.4% 4143 12.7% 
 2000 308 12.4% 280 12.0% 418 13.6% 4185 12.8% 
 2001 304 12.3% 267 11.5% 374 12.1% 4069 12.4% 
 2002 299 12.1% 296 12.7% 356 11.6% 4191 12.8% 
 2003 345 13.9% 324 13.9% 416 13.5% 4096 12.5% 
 2004 333 13.4% 350 15.0% 384 12.5% 4177 12.8% 
 Surgical resection within 6 months since diagnosis 
    
<0,001 
Yes 2065 83.2% 1944 83.5% 2592 84.1% 23908 73.1% 
 No 416 16.8% 385 16.5% 489 15.9% 8814 26.9% 
 Chemotherapy 
        
<0.001 
Yes 905 36.5% 751 32.2% 1069 34.7% 8542 26.1% 
 No 1559 62.8% 1564 67.2% 1982 64.3% 24180 73.9% 
 unknown 17 0.7% 14 0.6% 30 1.0% 0 0.0% 
 Radiotherapy 
        
<0.001 
Yes 375 15.1% 374 16.1% 586 19.0% 4027 12.3% 
 No 2095 84.4% 1943 83.4% 2467 80.1% 28695 87.7% 
 unknown 11 0.4% 12 0.5% 28 0.9% 0 0.0%   
* Including C18,8 
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Table 2: Distribution of Duke's stage before and after multiple imputation by site and country 
of residence 
         
 Complete Case analysis Multiple Imputation 
 France England France England 
 Colon Rectum Colon Rectum Colon Rectum Colon Rectum 
Duke's A 14.9% 31.7% 10.4% 22.1% 14.3% 27.2% 9.7% 19.2% 
Duke's B 33.3% 23.4% 34.0% 25.1% 31.9% 21.0% 31.0% 23.7% 
Duke's C 24.5% 20.9% 27.7% 29.6% 23.7% 20.2% 26.6% 28.7% 
"Duke's D" 27.2% 24.0% 27.9% 23.2% 30.0% 31.5% 32.7% 28.4% 
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Table 3 : Excess hazard ratios of death for country of residence during the first year since diagnosis, colorectal cancer, 1997-2004  
   
Multiple imputations for missing values Complete case analysis 
N° Variable   EHR 95%CI P-values EHR 95%CI 
P-
values 
Colon Cancer 
Model 1 
      
  
   
 
countries England 1.00
  
<0,001 1.00 
  
<0,001
   France 0.70 0.66 0.75   0.73 0.68 0.78   
Model 2 =Model 1 + Age, sex, period 
   
  
   
  
England 1.00 
  
<0,001 1.00 
  
<0,001
  France 0.70 0.65 0.74   0.73 0.68 0.78   
Model 3 =Model 2 +Cancer localisation* 
   
  
   
  
England 1.00 
  
<0,001 1.00 
  
<0,001
  France 0.70 0.65 0.74   0.81 0.75 0.86   
Model 4 =Model 3 +Stage 
    
  
   
  
England 1.00
  
<0,001 1.00 
  
<0,001
  France 0.68 0.64 0.74   0.75 0.70 0.80   
Model 5 a =Model 2 for Duke's A & B only 
   
  
   
  
England 1.00 
  
0.006 1.00 
  
0.033
  France 0.77 0.65 0.93   0.79 0.66 0.95   
Model 6 a =Model 5a for Duke's A & B + resection within 6 months 
 
  
   
  
England 1.00 
  
0.038 1.00 
  
0.038
  France 0.82 0.68 0.99   0.82 0.68 0.98   
Model 5 b =model 3 for Duke's C & D cancer only 
  
  
   
  
England 1.00 
  
<0,001 1.00 
  
<0,001
  France 0.67 0.63 0.72   0.74 0.69 0.80   
Model 6 b =model 5b for  Duke's C & D cancer only + resection within 6 months   
   
  
England 1.00 
  
<0.001 1.00 
  
<0.001
  France 0.79 0.74 0.85   0.83 0.77 0.90   
Model 7 b =model 5b for  Duke's C & D cancer only + resection within 6 months+ chemotherapy   
   
  
England 1.00 
  
0.095 1.00 
  
0.862
  France 0.94 0.88 1.01   1.00 0.92 1.06   
Model 8 b =model 5b for  Duke's C & D cancer only + resection within 6 months+ chemotherapy+ interaction (countries-chemotherapy) 
  
England 1.00 
  
0.918 1.00 
  
0.082 
Withoutchemotherapy France 0.99 0.92 1.07
 
1.07 0.99 1.17
 
  
England 1.00 
  
0.008 1.00 
  
0.001
Withchemotherapy France 0.81 0.69 0.94   0.76 0.65 0.89   
Rectum cancer 
Model 9 
 
England 1.00 
  
<0,001 1.00 
  
<0,001 
   France 0.76 0.68 0.86   0.74 0.64 0.85   
Model 10 =Model 9 + Age, sex, period 
   
  
   
  
England 1.00 
  
<0,001 1.00 
  
<0,001
  France 0.76 0.67 0.85   0.73 0.63 0.84   
Model 11 =Model 10 + Stage 
    
  
   
  
England 1.00
  
<0,001 1.00 
  
<0,001
  France 0.69 0.61 0.77   0.67 0.58 0.77   
Model 11a  =Model 10 for duke's A & B cancer only 
  
  
   
  
England 1.00 
  
0.048 1.00 
  
0.065
  France 0.70 0.49 0.99   0.71 0.50 1.02   
Model 12a  =Model 10 for Duke's A & B cancer only + resection within 6 months   
   
  
England 1.00 
  
0.13 1.00 
  
0.353
 
 France 0.74 0.51 1.08   0.83 0.57 1.22   
Model 11b  =Model 10 for Duke's C & D cancer only 
  
  
   
  
England 1.00 
  
<0.001 1.00 
  
<0.001
  
France 0.69 0.61 0.77   0.66 0.57 0.77   
Model 12b  =Model 11a for Duke's C & D cancer only + resection within 6 months   
   
  
England 1.00 
  
<0.001 1.00 
  
<0.001
 
 France 0.73 0.64 0.82   0.77 0.66 0.89   
Model 13b =Model 11a for Duke's C & D cancer only + resection within 6 months + Radiotherapy + 
Chemotherapy   
   
  
England 1.00 
  
0.575 1.00 
  
0.637
  France 0.96 0.85 1.09   1.01 0.86 1.10   
* Unknow Colon Cancer (C18.8 or C18.9) were kept in complete case analysis 
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Table 4 : Excess hazard ratios of death for country of residence after the first year since diagnosis (2-5 years), colorectal 
cancer, 1997-2004  
   
Multiple imputations for missing values Complete case analysis 
N° Variable   EHR 95%CI P-values EHR 95%CI 
P-
values 
Colon Cancer 
Model 1 
      
  
   
 
countries England 1.00 
  
0.571 1.00 
  
0.407 
   France 1.02 0.95 1.11   1.03 0.95 1.11   
Model 2 =Model 1 + Age, sex, period 
   
  
   
  
England 1.00 
  
0.518 1.00 
  
0.458 
    France 1.03 0.95 1.11   1.03 0.95 1.12   
Model 3 =Model 2 +Cancer localisation 
   
  
   
  
England 1.00 
  
0.472 1.00 
  
0.414 
    France 1.03 0.95 1.11   1.03 0.95 1.12   
Model 4 =Model 3 +Stage 
    
  
   
  
England 1.00 
  
0.032 1.00 
  
0.036 
    France 0.92 0.85 0.99   0.92 0.85 0.99   
Model 5 a =Model 3 for duke's A & B cancer only 
  
  
   
  
England 1.00 
  
0.623 1.00 
  
0.829 
    France 1.05 0.85 1.31   1.02 0.82 1.28   
Model 6 a =Model 5a for Duke's A & B cancer only + resection within 6 months   
   
  
England 1.00 
  
0.318 1.00 
  
0.737 
    France 1.07 0.86 1.33   1.04 0.84 1.30   
Model 5 b =model 3 for Duke's C & Dcancer only 
  
  
   
  
England 1.00 
  
0.449 1.00 
  
0.199 
    France 1.03 0.95 1.12   1.06 0.97 1.15   
Model 6 b =model 5b for Duke's C & D cancer only + resection surgery within 6 months   
   
  
England 1.00 
  
0.25 1.00 
  
0.449 
    France 1.04 0.97 1.14   1.03 0.95 1.12   
Rectum cancer 
Model 9 
      
  
   
  
England 1.00
  
0.733 1.00 
  
0.891
  France 0.98 0.87 1.10   1.01 0.90 1.14   
Model 10 =Model 9 + Age, sex, period 
   
  
   
  
England 1.00 
  
0.807 1.00 
  
0.829 
    France 0.99 0.88 1.11   1.01 0.89 1.15   
Model 11 =Model 10 + Stage 
    
  
   
  
England 1.00 
  
0.127 1.00 
  
0.542 
    France 0.91 0.81 1.03   1.04 0.92 1.18   
Model 11a  =Model 9 for Duke's A & B cancer only 
  
  
   
  
England 1.00 
  
0.161 1.00 
  
0.734 
    France 0.81 0.60 1.09   0.89 0.45 1.76   
Model 11b  =Model 11a for Duke's C & D cancer only 
  
  
   
  
England 1.00 
  
0.011 1.00 
  
<0.001 
    France 1.17 1.03 1.31   1.36 1.19 1.56   
Model 12b  =Model 11a for Duke's C & D cancer only + resection within 6 months   
   
  
England 1.00 
  
0.331 1.00 
  
<0.001
  France 1.06 0.93 1.21   1.39 1.22 1.60   
Model 13b  =Model 12a for Duke's C & D cancer only + radiotherapy + chemotherapy   
   
  
England 1.00 
  
0.218 1.00 
  
<0.001 
  France 1.09 0.95 1.24   1.45 1.26 1.66   
* Unknow Colon Cancer (C18.8 or C18.9) were kept in complete case analysis 
    
